{"protocolSection": {"identificationModule": {"nctId": "NCT01922089", "orgStudyIdInfo": {"id": "CLCZ696B2228"}, "secondaryIdInfos": [{"id": "2013-001835-33", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients", "officialTitle": "A Multicenter, Randomized, Double-blind, Parallel Group Study to Assess the Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients Comparing Two Titration Regimens", "acronym": "TITRATION"}, "statusModule": {"statusVerifiedDate": "2015-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-11"}, "primaryCompletionDateStruct": {"date": "2014-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-08-12", "studyFirstSubmitQcDate": "2013-08-13", "studyFirstPostDateStruct": {"date": "2013-08-14", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-07-16", "resultsFirstSubmitQcDate": "2015-09-16", "resultsFirstPostDateStruct": {"date": "2015-10-15", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-09-16", "lastUpdatePostDateStruct": {"date": "2015-10-15", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of this study is to assess the safety and tolerability of initiating LCZ696 in heart failure patients with reduced ejection fraction (HF-rEF) using conservative (reaching target dose over 6 weeks) and condensed (reaching target dose over 3 weeks) up-titration regimens."}, "conditionsModule": {"conditions": ["Heart Failure With Reduced Ejection Fraction"], "keywords": ["Heart failure, reduced ejection fraction, LCZ696, titration, safety, tolerability"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 498, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "LCZ696 Condensed", "type": "EXPERIMENTAL", "description": "Up-titration to LCZ696 200 mg twice daily (bid) over 3 weeks", "interventionNames": ["Drug: LCZ696"]}, {"label": "LCZ696 Conservative", "type": "EXPERIMENTAL", "description": "Up-titration to LCZ696 200 mg bid over 6 weeks", "interventionNames": ["Drug: LCZ696"]}], "interventions": [{"type": "DRUG", "name": "LCZ696", "description": "LCZ696 50 mg/100 mg/200 mg bid", "armGroupLabels": ["LCZ696 Condensed", "LCZ696 Conservative"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants Experiencing Hypotension, Renal Dysfunction, Hyperkalemia and Angioedema and by Renin-Angiotensin-Aldosterone System (RAAS) Stratum (High vs. Low)", "description": "Participants experiencing hypotension, renal dysfunction, hyperkalemia and angioedema and by Renin-Angiotensin-Aldosterone System (RAAS) stratum (high vs. low) High RAAS stratum Patients receiving \\> 160 mg of valsartan or \\> 10 mg total daily dose of enalapril, or equivalent doses of other ARBs/ACEIs, respectively, at screening Low RAAS stratum: Patients receiving \u2264 160 mg of valsartan or \u2264 10 mg total daily dose of enalapril, or equivalent doses of other ARBs/ACEIs, respectively, at screening. This stratum also included patients who were not on an ACEI or an ARB 4 weeks prior to screening (i.e., ACEI/ARB-na\u00efve patients)", "timeFrame": "12 weeks"}], "secondaryOutcomes": [{"measure": "Number of Participants Who Achieved Treatment Success Over the 12 Weeks and by Renin-Angiotensin-Aldosterone System (RAAS) Stratum (High vs. Low)", "description": "Treatment success was defined as the number of participants who achieved and maintained LCZ696 200 mg bid without any dose interruption or down-titration over 12 weeks and by Renin-Angiotensin-Aldosterone System (RAAS) stratum (high vs. low) High RAAS stratum Patients receiving \\> 160 mg of valsartan or \\> 10 mg total daily dose of enalapril, or equivalent doses of other ARBs/ACEIs, respectively, at screening Low RAAS stratum: Patients receiving \u2264 160 mg of valsartan or \u2264 10 mg total daily dose of enalapril, or equivalent doses of other ARBs/ACEIs, respectively, at screening. This stratum also included patients who were not on an ACEI or an ARB 4 weeks prior to screening (i.e., ACEI/ARB-na\u00efve patients)", "timeFrame": "12 weeks"}, {"measure": "Number of Participants Who Tolerated Study Medication for at Least the Last Two Weeks of the Study and by Renin-Angiotensin-Aldosterone System (RAAS) Stratum (High vs. Low).", "description": "Tolerability was assessed as the number of participants who achieved LCZ696 200 mg bid and maintained this dose for at least 2 weeks before study completion, regardless of previous dose interruption or down-titration and by Renin-Angiotensin-Aldosterone System (RAAS) stratum (high vs. low) High RAAS stratum Patients receiving \\> 160 mg of valsartan or \\> 10 mg total daily dose of enalapril, or equivalent doses of other ARBs/ACEIs, respectively, at screening Low RAAS stratum: Patients receiving \u2264 160 mg of valsartan or \u2264 10 mg total daily dose of enalapril, or equivalent doses of other ARBs/ACEIs, respectively, at screening. This stratum also included patients who were not on an ACEI or an ARB 4 weeks prior to screening (i.e., ACEI/ARB-na\u00efve patients)", "timeFrame": "12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 years; CHF with New York Heart Association class II-IV; left ventricular ejection fraction \u2264 35%; on beta blockers\n\nExclusion Criteria:\n\n* Potassium \\> 5.2 mmol/l; estimated glomerular filtration rate \\< 30 ml/min/1.73 m2; systolic blood pressure \\<100 mmHg or \\> 180 mmHg; history of intolerance to recommended target doses of angiotensin converting enzyme inhibitors or angiotensin receptor blockers\n\nOther protocol-defined inclusion/exclusion criteria may apply.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Anchorage", "state": "Alaska", "zip": "99508", "country": "United States", "geoPoint": {"lat": 61.21806, "lon": -149.90028}}, {"facility": "Novartis Investigative Site", "city": "Gilbert", "state": "Arizona", "zip": "85297", "country": "United States", "geoPoint": {"lat": 33.35283, "lon": -111.78903}}, {"facility": "Novartis Investigative Site", "city": "Tucson", "state": "Arizona", "zip": "85710", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "Novartis Investigative Site", "city": "Anaheim", "state": "California", "zip": "92801", "country": "United States", "geoPoint": {"lat": 33.83529, "lon": -117.9145}}, {"facility": "Novartis Investigative Site", "city": "Torrance", "state": "California", "zip": "90502", "country": "United States", "geoPoint": {"lat": 33.83585, "lon": -118.34063}}, {"facility": "Novartis Investigative Site", "city": "Atlantis", "state": "Florida", "zip": "33462", "country": "United States", "geoPoint": {"lat": 26.5909, "lon": -80.10088}}, {"facility": "Novartis Investigative Site", "city": "Chiefland", "state": "Florida", "zip": "32626", "country": "United States", "geoPoint": {"lat": 29.47496, "lon": -82.85984}}, {"facility": "Novartis Investigative Site", "city": "Aurora", "state": "Illinois", "zip": "60504", "country": "United States", "geoPoint": {"lat": 41.76058, "lon": -88.32007}}, {"facility": "Novartis Investigative Site", "city": "Peoria", "state": "Illinois", "zip": "61602", "country": "United States", "geoPoint": {"lat": 40.69365, "lon": -89.58899}}, {"facility": "Novartis Investigative Site", "city": "Evansville", "state": "Indiana", "zip": "47714", "country": "United States", "geoPoint": {"lat": 37.97476, "lon": -87.55585}}, {"facility": "Novartis Investigative Site", "city": "Slidell", "state": "Louisiana", "zip": "70458", "country": "United States", "geoPoint": {"lat": 30.27519, "lon": -89.78117}}, {"facility": "Novartis Investigative Site", "city": "Minneapolis", "state": "Minnesota", "zip": "55417", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Novartis Investigative Site", "city": "St. Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Novartis Investigative Site", "city": "Buffalo", "state": "New York", "zip": "14215", "country": "United States", "geoPoint": {"lat": 42.88645, "lon": -78.87837}}, {"facility": "Novartis Investigative Site", "city": "Laurelton", "state": "New York", "zip": "11422", "country": "United States", "geoPoint": {"lat": 40.67016, "lon": -73.74664}}, {"facility": "Novartis Investigative Site", "city": "Marion", "state": "Ohio", "zip": "43302", "country": "United States", "geoPoint": {"lat": 40.58867, "lon": -83.12852}}, {"facility": "Novartis Investigative Site", "city": "Oak Ridge", "state": "Tennessee", "zip": "37830", "country": "United States", "geoPoint": {"lat": 36.01036, "lon": -84.26964}}, {"facility": "Novartis Investigative Site", "city": "Dallas", "state": "Texas", "zip": "75231", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Novartis Investigative Site", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Novartis Investigative Site", "city": "Houston", "state": "Texas", "zip": "77094", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Novartis Investigative Site", "city": "Livingston", "state": "Texas", "zip": "77351", "country": "United States", "geoPoint": {"lat": 30.71103, "lon": -94.93299}}, {"facility": "Novartis Investigative Site", "city": "Tacoma", "state": "Washington", "zip": "98405", "country": "United States", "geoPoint": {"lat": 47.25288, "lon": -122.44429}}, {"facility": "Novartis Investigative Site", "city": "Gabrovo", "zip": "5300", "country": "Bulgaria", "geoPoint": {"lat": 42.87472, "lon": 25.33417}}, {"facility": "Novartis Investigative Site", "city": "Plovdiv", "zip": "4000", "country": "Bulgaria", "geoPoint": {"lat": 42.15, "lon": 24.75}}, {"facility": "Novartis Investigative Site", "city": "Plovdiv", "zip": "4004", "country": "Bulgaria", "geoPoint": {"lat": 42.15, "lon": 24.75}}, {"facility": "Novartis Investigative Site", "city": "Smolian", "zip": "4700", "country": "Bulgaria"}, {"facility": "Novartis Investigative Site", "city": "Sofia", "zip": "1202", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Novartis Investigative Site", "city": "Sofia", "zip": "1407", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Novartis Investigative Site", "city": "Jyvaskyla", "zip": "40620", "country": "Finland", "geoPoint": {"lat": 62.24147, "lon": 25.72088}}, {"facility": "Novartis Investigative Site", "city": "Tampere", "zip": "33520", "country": "Finland", "geoPoint": {"lat": 61.49911, "lon": 23.78712}}, {"facility": "Novartis Investigative Site", "city": "Bad Krozingen", "zip": "79189", "country": "Germany", "geoPoint": {"lat": 47.91933, "lon": 7.69045}}, {"facility": "Novartis Investigative Site", "city": "Berlin-Buch", "zip": "13125", "country": "Germany"}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "10367", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "10787", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "10789", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "13055", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "13347", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "13353", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "13405", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Dietzenbach", "zip": "63128", "country": "Germany", "geoPoint": {"lat": 50.00976, "lon": 8.77783}}, {"facility": "Novartis Investigative Site", "city": "Ebersbach", "zip": "02730", "country": "Germany", "geoPoint": {"lat": 51.00762, "lon": 14.58621}}, {"facility": "Novartis Investigative Site", "city": "Frankfurt", "zip": "60594", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Novartis Investigative Site", "city": "G\u00f6ttingen", "zip": "D-37075", "country": "Germany", "geoPoint": {"lat": 51.53443, "lon": 9.93228}}, {"facility": "Novartis Investigative Site", "city": "Hassloch", "zip": "67454", "country": "Germany", "geoPoint": {"lat": 49.36278, "lon": 8.25806}}, {"facility": "Novartis Investigative Site", "city": "Huy / OT Anderbeck", "zip": "38836", "country": "Germany"}, {"facility": "Novartis Investigative Site", "city": "Ingelheim", "zip": "55218", "country": "Germany"}, {"facility": "Novartis Investigative Site", "city": "Kelkheim", "zip": "65779", "country": "Germany"}, {"facility": "Novartis Investigative Site", "city": "Kleve", "zip": "47533", "country": "Germany", "geoPoint": {"lat": 51.78826, "lon": 6.13865}}, {"facility": "Novartis Investigative Site", "city": "Leipzig", "zip": "04315", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "Novartis Investigative Site", "city": "Mainz", "zip": "55116", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "Novartis Investigative Site", "city": "Mainz", "zip": "55131", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "Novartis Investigative Site", "city": "M\u00fchlheim", "zip": "45468", "country": "Germany", "geoPoint": {"lat": 50.11667, "lon": 8.83333}}, {"facility": "Novartis Investigative Site", "city": "Siegen", "zip": "57072", "country": "Germany", "geoPoint": {"lat": 50.87481, "lon": 8.02431}}, {"facility": "Novartis Investigative Site", "city": "Straubing", "zip": "94315", "country": "Germany", "geoPoint": {"lat": 48.88126, "lon": 12.57385}}, {"facility": "Novartis Investigative Site", "city": "Wuerzburg", "zip": "97078", "country": "Germany", "geoPoint": {"lat": 49.79391, "lon": 9.95121}}, {"facility": "Novartis Investigative Site", "city": "Budapest", "zip": "1042", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Novartis Investigative Site", "city": "Budapest", "zip": "1145", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Novartis Investigative Site", "city": "Budapest", "zip": "H-1096", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Novartis Investigative Site", "city": "Debrecen", "zip": "4032", "country": "Hungary", "geoPoint": {"lat": 47.53333, "lon": 21.63333}}, {"facility": "Novartis Investigative Site", "city": "Mosonmagyarovar", "zip": "9200", "country": "Hungary", "geoPoint": {"lat": 47.86789, "lon": 17.26994}}, {"facility": "Novartis Investigative Site", "city": "Nyiregyh\u00e1za", "zip": "4400", "country": "Hungary", "geoPoint": {"lat": 47.95539, "lon": 21.71671}}, {"facility": "Novartis Investigative Site", "city": "Pecs", "zip": "7623", "country": "Hungary", "geoPoint": {"lat": 46.08333, "lon": 18.23333}}, {"facility": "Novartis Investigative Site", "city": "Szekesfehervar", "zip": "8000", "country": "Hungary", "geoPoint": {"lat": 47.18995, "lon": 18.41034}}, {"facility": "Novartis Investigative Site", "city": "Aosta", "state": "AO", "zip": "11100", "country": "Italy", "geoPoint": {"lat": 45.73764, "lon": 7.31722}}, {"facility": "Novartis Investigative Site", "city": "Cortona", "state": "AR", "zip": "52044", "country": "Italy", "geoPoint": {"lat": 43.27467, "lon": 11.98533}}, {"facility": "Novartis Investigative Site", "city": "Bergamo", "state": "BG", "zip": "24128", "country": "Italy", "geoPoint": {"lat": 45.69601, "lon": 9.66721}}, {"facility": "Novartis Investigative Site", "city": "Bologna", "state": "BO", "zip": "40138", "country": "Italy", "geoPoint": {"lat": 44.49381, "lon": 11.33875}}, {"facility": "Novartis Investigative Site", "city": "Cona", "state": "FE", "zip": "44100", "country": "Italy", "geoPoint": {"lat": 44.80583, "lon": 11.7069}}, {"facility": "Novartis Investigative Site", "city": "Albano Laziale", "state": "RM", "zip": "00041", "country": "Italy", "geoPoint": {"lat": 41.72748, "lon": 12.659}}, {"facility": "Novartis Investigative Site", "city": "Roma", "state": "RM", "zip": "00163", "country": "Italy", "geoPoint": {"lat": 41.89193, "lon": 12.51133}}, {"facility": "Novartis Investigative Site", "city": "Sassari", "state": "SS", "zip": "07100", "country": "Italy", "geoPoint": {"lat": 40.72586, "lon": 8.55552}}, {"facility": "Novartis Investigative Site", "city": "Vittorio Veneto", "state": "TV", "zip": "31029", "country": "Italy", "geoPoint": {"lat": 45.98026, "lon": 12.30065}}, {"facility": "Novartis Investigative Site", "city": "San Daniele Del Friuli", "state": "UD", "zip": "33038", "country": "Italy", "geoPoint": {"lat": 46.15714, "lon": 13.00726}}, {"facility": "Novartis Investigative Site", "city": "San Juan", "zip": "00936-6528", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}, {"facility": "Novartis Investigative Site", "city": "Brezno", "state": "Slovak Republic", "zip": "977 42", "country": "Slovakia", "geoPoint": {"lat": 48.80431, "lon": 19.63631}}, {"facility": "Novartis Investigative Site", "city": "Nitra", "state": "Slovak Republic", "zip": "949 01", "country": "Slovakia", "geoPoint": {"lat": 48.30763, "lon": 18.08453}}, {"facility": "Novartis Investigative Site", "city": "Svidnik", "state": "Slovak Republic", "zip": "08901", "country": "Slovakia", "geoPoint": {"lat": 49.30819, "lon": 21.5703}}, {"facility": "Novartis Investigative Site", "city": "Bratislava", "zip": "821 07", "country": "Slovakia", "geoPoint": {"lat": 48.14816, "lon": 17.10674}}, {"facility": "Novartis Investigative Site", "city": "Bratislava", "zip": "83301", "country": "Slovakia", "geoPoint": {"lat": 48.14816, "lon": 17.10674}}, {"facility": "Novartis Investigative Site", "city": "Kosice", "zip": "040 01", "country": "Slovakia", "geoPoint": {"lat": 48.71395, "lon": 21.25808}}, {"facility": "Novartis Investigative Site", "city": "Lucenec", "zip": "98439", "country": "Slovakia", "geoPoint": {"lat": 48.33249, "lon": 19.66708}}, {"facility": "Novartis Investigative Site", "city": "Nove Zamky", "zip": "940 01", "country": "Slovakia", "geoPoint": {"lat": 47.98544, "lon": 18.16195}}, {"facility": "Novartis Investigative Site", "city": "Trebisov", "zip": "075 01", "country": "Slovakia", "geoPoint": {"lat": 48.62858, "lon": 21.71954}}, {"facility": "Novartis Investigative Site", "city": "Almeria", "state": "Andalucia", "zip": "04120", "country": "Spain", "geoPoint": {"lat": 36.83814, "lon": -2.45974}}, {"facility": "Novartis Investigative Site", "city": "Malaga", "state": "Andalucia", "zip": "29010", "country": "Spain", "geoPoint": {"lat": 36.72016, "lon": -4.42034}}, {"facility": "Novartis Investigative Site", "city": "Sanlucar de Barrameda", "state": "Andalucia", "zip": "11540", "country": "Spain", "geoPoint": {"lat": 36.77808, "lon": -6.3515}}, {"facility": "Novartis Investigative Site", "city": "Sevilla", "state": "Andalucia", "zip": "41014", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "Novartis Investigative Site", "city": "Villamartin", "state": "Cadiz", "zip": "11650", "country": "Spain", "geoPoint": {"lat": 36.85979, "lon": -5.64485}}, {"facility": "Novartis Investigative Site", "city": "Barcelona", "state": "Catalunya", "zip": "08035", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Novartis Investigative Site", "city": "A Coruna", "state": "Galicia", "zip": "15006", "country": "Spain", "geoPoint": {"lat": 43.37135, "lon": -8.396}}, {"facility": "Novartis Investigative Site", "city": "Madrid", "zip": "28007", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Novartis Investigative Site", "city": "Haydarpasa/Istanbul", "zip": "34668", "country": "Turkey"}, {"facility": "Novartis Investigative Site", "city": "Istanbul", "zip": "34304", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "Novartis Investigative Site", "city": "Kocaeli", "zip": "41380", "country": "Turkey", "geoPoint": {"lat": 39.62497, "lon": 27.51145}}, {"facility": "Novartis Investigative Site", "city": "Mersin", "zip": "33079", "country": "Turkey", "geoPoint": {"lat": 36.79526, "lon": 34.61792}}, {"facility": "Novartis Investigative Site", "city": "Sivas", "zip": "58140", "country": "Turkey", "geoPoint": {"lat": 39.74833, "lon": 37.01611}}, {"facility": "Novartis Investigative Site", "city": "Dorchester", "state": "Dorset", "zip": "DT1 2JY", "country": "United Kingdom", "geoPoint": {"lat": 50.71667, "lon": -2.43333}}, {"facility": "Novartis Investigative Site", "city": "St Leonards on Sea", "state": "East Sussex", "zip": "TN37 7RD", "country": "United Kingdom", "geoPoint": {"lat": 50.85565, "lon": 0.5452}}, {"facility": "Novartis Investigative Site", "city": "Oldham", "state": "Lancashire", "zip": "OL1 2JH", "country": "United Kingdom", "geoPoint": {"lat": 53.54051, "lon": -2.1183}}, {"facility": "Novartis Investigative Site", "city": "Gateshead", "state": "Tyne and Wear", "zip": "NE9 6SX", "country": "United Kingdom", "geoPoint": {"lat": 54.96209, "lon": -1.60168}}, {"facility": "Novartis Investigative Site", "city": "Bath", "zip": "BA1 3NG", "country": "United Kingdom", "geoPoint": {"lat": 51.3751, "lon": -2.36172}}, {"facility": "Novartis Investigative Site", "city": "Bradford", "zip": "BD9 6RJ", "country": "United Kingdom", "geoPoint": {"lat": 53.79391, "lon": -1.75206}}, {"facility": "Novartis Investigative Site", "city": "Coventry", "zip": "CV2 2DX", "country": "United Kingdom", "geoPoint": {"lat": 52.40656, "lon": -1.51217}}, {"facility": "Novartis Investigative Site", "city": "Harrow", "zip": "HA1 3UJ", "country": "United Kingdom", "geoPoint": {"lat": 51.57142, "lon": -0.33371}}, {"facility": "Novartis Investigative Site", "city": "Nuneaton", "zip": "CV10 7DJ", "country": "United Kingdom", "geoPoint": {"lat": 52.52323, "lon": -1.46523}}]}, "referencesModule": {"references": [{"pmid": "29164797", "type": "DERIVED", "citation": "Senni M, McMurray JJV, Wachter R, McIntyre HF, Anand IS, Duino V, Sarkar A, Shi V, Charney A. Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. Eur J Heart Fail. 2018 Mar;20(3):491-500. doi: 10.1002/ejhf.1054. Epub 2017 Nov 22."}, {"pmid": "27170530", "type": "DERIVED", "citation": "Senni M, McMurray JJ, Wachter R, McIntyre HF, Reyes A, Majercak I, Andreka P, Shehova-Yankova N, Anand I, Yilmaz MB, Gogia H, Martinez-Selles M, Fischer S, Zilahi Z, Cosmi F, Gelev V, Galve E, Gomez-Doblas JJ, Nociar J, Radomska M, Sokolova B, Volterrani M, Sarkar A, Reimund B, Chen F, Charney A. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016 Sep;18(9):1193-202. doi: 10.1002/ejhf.548. Epub 2016 May 12."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "LCZ696 Condensed", "description": "Up-titration to LCZ696 200 mg twice daily (bid) over 3 weeks"}, {"id": "FG001", "title": "LCZ696 Conservative", "description": "Up-titration to LCZ696 200 mg bid over 6 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "247"}, {"groupId": "FG001", "numSubjects": "251"}]}, {"type": "Safety Set", "achievements": [{"groupId": "FG000", "numSubjects": "246"}, {"groupId": "FG001", "numSubjects": "251"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "208"}, {"groupId": "FG001", "numSubjects": "221"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "39"}, {"groupId": "FG001", "numSubjects": "30"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "13"}]}, {"type": "Protocol Deviation", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "LCZ696 Condensed", "description": "Up-titration to LCZ696 200 mg twice daily (bid) over 3 weeks"}, {"id": "BG001", "title": "LCZ696 Conservative", "description": "Up-titration to LCZ696 200 mg bid over 6 weeks"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "247"}, {"groupId": "BG001", "value": "251"}, {"groupId": "BG002", "value": "498"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "64.2", "spread": "11.86"}, {"groupId": "BG001", "value": "63.8", "spread": "10.94"}, {"groupId": "BG002", "value": "64.0", "spread": "11.39"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "56"}, {"groupId": "BG001", "value": "50"}, {"groupId": "BG002", "value": "106"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "191"}, {"groupId": "BG001", "value": "201"}, {"groupId": "BG002", "value": "392"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants Experiencing Hypotension, Renal Dysfunction, Hyperkalemia and Angioedema and by Renin-Angiotensin-Aldosterone System (RAAS) Stratum (High vs. Low)", "description": "Participants experiencing hypotension, renal dysfunction, hyperkalemia and angioedema and by Renin-Angiotensin-Aldosterone System (RAAS) stratum (high vs. low) High RAAS stratum Patients receiving \\> 160 mg of valsartan or \\> 10 mg total daily dose of enalapril, or equivalent doses of other ARBs/ACEIs, respectively, at screening Low RAAS stratum: Patients receiving \u2264 160 mg of valsartan or \u2264 10 mg total daily dose of enalapril, or equivalent doses of other ARBs/ACEIs, respectively, at screening. This stratum also included patients who were not on an ACEI or an ARB 4 weeks prior to screening (i.e., ACEI/ARB-na\u00efve patients)", "populationDescription": "Full Analysis Set (FAS) consisted of all randomized patients with the exception of mis-randomized patients who had not received the study drug, but had been inadvertently randomized into the study. Following the intent-to-treat principle, patients were analyzed according to the treatment to which they were assigned at randomization.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "LCZ696 Condensed", "description": "Up-titration to LCZ696 200 mg twice daily (bid) over 3 weeks"}, {"id": "OG001", "title": "LCZ696 Conservative", "description": "Up-titration to LCZ696 200 mg bid over 6 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "247"}, {"groupId": "OG001", "value": "251"}]}], "classes": [{"title": "Hypotension High RAAS (n=120, 127)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Hypotension Low RAAS (n=127, 124)", "categories": [{"measurements": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "14"}]}]}, {"title": "Hypotension ALL", "categories": [{"measurements": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "21"}]}]}, {"title": "Renal Dysfunction High RAAS (n=120, 127)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "9"}]}]}, {"title": "Renal Dysfunction Low RAAS (n=127, 124)", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "10"}]}]}, {"title": "Renal Dysfunction ALL", "categories": [{"measurements": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "19"}]}]}, {"title": "Hyperkalemia High RAAS (n=120, 127)", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "Hyperkalemia Low RAAS (n=127, 124)", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": "Hyperkalemia ALL", "categories": [{"measurements": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "11"}]}]}, {"title": "Angioedema High RAAS (n=120, 127)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Angioedema Low RAAS (n=127, 124)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Angioedema ALL", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Who Achieved Treatment Success Over the 12 Weeks and by Renin-Angiotensin-Aldosterone System (RAAS) Stratum (High vs. Low)", "description": "Treatment success was defined as the number of participants who achieved and maintained LCZ696 200 mg bid without any dose interruption or down-titration over 12 weeks and by Renin-Angiotensin-Aldosterone System (RAAS) stratum (high vs. low) High RAAS stratum Patients receiving \\> 160 mg of valsartan or \\> 10 mg total daily dose of enalapril, or equivalent doses of other ARBs/ACEIs, respectively, at screening Low RAAS stratum: Patients receiving \u2264 160 mg of valsartan or \u2264 10 mg total daily dose of enalapril, or equivalent doses of other ARBs/ACEIs, respectively, at screening. This stratum also included patients who were not on an ACEI or an ARB 4 weeks prior to screening (i.e., ACEI/ARB-na\u00efve patients)", "populationDescription": "Evaluable patients in FAS with the exception of misrandomized patients who didn't received drug, but had been randomized into the study, excluding patients who discontinued the study prior to completion of 12 wks. Following the intent-to-treat principle, patients were analyzed according to the treatment to which they were assigned at randomization.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "LCZ696 Condensed", "description": "Up-titration to LCZ696 200 mg twice daily (bid) over 3 weeks"}, {"id": "OG001", "title": "LCZ696 Conservative", "description": "Up-titration to LCZ696 200 mg bid over 6 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "230"}, {"groupId": "OG001", "value": "236"}]}], "classes": [{"title": "High RAAS (n=109,117)", "categories": [{"measurements": [{"groupId": "OG000", "value": "90"}, {"groupId": "OG001", "value": "98"}]}]}, {"title": "Low RAAS (n=121,119)", "categories": [{"measurements": [{"groupId": "OG000", "value": "89"}, {"groupId": "OG001", "value": "101"}]}]}, {"title": "ALL (n=230,236)", "categories": [{"measurements": [{"groupId": "OG000", "value": "179"}, {"groupId": "OG001", "value": "199"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Who Tolerated Study Medication for at Least the Last Two Weeks of the Study and by Renin-Angiotensin-Aldosterone System (RAAS) Stratum (High vs. Low).", "description": "Tolerability was assessed as the number of participants who achieved LCZ696 200 mg bid and maintained this dose for at least 2 weeks before study completion, regardless of previous dose interruption or down-titration and by Renin-Angiotensin-Aldosterone System (RAAS) stratum (high vs. low) High RAAS stratum Patients receiving \\> 160 mg of valsartan or \\> 10 mg total daily dose of enalapril, or equivalent doses of other ARBs/ACEIs, respectively, at screening Low RAAS stratum: Patients receiving \u2264 160 mg of valsartan or \u2264 10 mg total daily dose of enalapril, or equivalent doses of other ARBs/ACEIs, respectively, at screening. This stratum also included patients who were not on an ACEI or an ARB 4 weeks prior to screening (i.e., ACEI/ARB-na\u00efve patients)", "populationDescription": "Evaluable patients in FAS with the exception of misrandomized patients who didn't received drug, but had been randomized into the study, excluding patients who discontinued the study prior to completion of 12 wks. Following the intent-to-treat principle, patients were analyzed according to the treatment to which they were assigned at randomization.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "LCZ696 Condensed", "description": "Up-titration to LCZ696 200 mg twice daily (bid) over 3 weeks"}, {"id": "OG001", "title": "LCZ696 Conservative", "description": "Up-titration to LCZ696 200 mg bid over 6 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "230"}, {"groupId": "OG001", "value": "236"}]}], "classes": [{"title": "High RAAS (n=109,117)", "categories": [{"measurements": [{"groupId": "OG000", "value": "94"}, {"groupId": "OG001", "value": "103"}]}]}, {"title": "Low RAAS (n=121,119)", "categories": [{"measurements": [{"groupId": "OG000", "value": "97"}, {"groupId": "OG001", "value": "103"}]}]}, {"title": "ALL (n=230,236)", "categories": [{"measurements": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "206"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "description": "Hyperkalemia in primary outcome is when patient experiences any AE after randomization with preferred term Hyperkalaemia or Blood potassium increased and AE table has incidences of AEs on or after randomization by preferred terms which exceeds a threshold of 2%. therefore 3 less cases than Primary OM.", "eventGroups": [{"id": "EG000", "title": "LCZ696 Condensed", "description": "Up-titration to LCZ696 200 mg twice daily (bid) over 3 weeks", "seriousNumAffected": 21, "seriousNumAtRisk": 246, "otherNumAffected": 72, "otherNumAtRisk": 246}, {"id": "EG001", "title": "LCZ696 Conservative", "description": "Up-titration to LCZ696 200 mg bid over 6 weeks", "seriousNumAffected": 14, "seriousNumAtRisk": 251, "otherNumAffected": 52, "otherNumAtRisk": 251}], "seriousEvents": [{"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 251}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 251}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 251}]}, {"term": "Cardiac failure acute", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 251}]}, {"term": "Cardiac failure chronic", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 251}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 251}]}, {"term": "Cardiac ventricular thrombosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 251}]}, {"term": "Cardiogenic shock", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 251}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 251}]}, {"term": "Coronary artery stenosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 251}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 251}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 251}]}, {"term": "Ventricular fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 251}]}, {"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 251}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 251}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 251}]}, {"term": "Gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 251}]}, {"term": "Cardiac death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 251}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 251}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 251}]}, {"term": "Hepatic cyst", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 251}]}, {"term": "Gastrointestinal infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 251}]}, {"term": "Infected skin ulcer", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 251}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 251}]}, {"term": "Staphylococcal sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 251}]}, {"term": "Ankle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 251}]}, {"term": "Procedural complication", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 251}]}, {"term": "International normalised ratio increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 251}]}, {"term": "Bladder neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 251}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 251}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 251}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 251}]}, {"term": "Renal failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 251}]}, {"term": "Renal failure acute", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 251}]}, {"term": "Renal failure chronic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 251}]}, {"term": "Postmenopausal haemorrhage", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 251}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 251}]}, {"term": "Pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 251}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 251}]}], "otherEvents": [{"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 251}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 251}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 251}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 251}]}, {"term": "Hypokalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 251}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 251}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 251}]}, {"term": "Renal failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 251}]}, {"term": "Renal impairment", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 251}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 251}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 24, "numAtRisk": 246}, {"groupId": "EG001", "numAffected": 21, "numAtRisk": 251}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Norway"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000549068", "term": "Sacubitril and valsartan sodium hydrate drug combination"}], "ancestors": [{"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M350410", "name": "Sacubitril and valsartan sodium hydrate drug combination", "asFound": "Allopurinol", "relevance": "HIGH"}, {"id": "M301", "name": "Valsartan", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnAg", "name": "Antihypertensive Agents"}]}}, "hasResults": true}